Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

O1378

Supelco

Oxycodone hydrochloride

analytical standard

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H21NO4 · HCl
CAS Number:
124-90-3
Molecular Weight:
351.82
EC Number:
204-717-1
MDL number:
MFCD00137583
UNSPSC Code:
41116107
PubChem Substance ID:
329818896
NACRES:
NA.24

grade

analytical standard

Quality Level

200

drug control

USDEA Schedule II; Home Office Schedule 2; stupéfiant (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

SMILES string

Cl.[H][C@@]12Oc3c(OC)ccc4C[C@H]5N(C)CC[C@@]1(c34)[C@@]5(O)CCC2=O

InChI

1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

InChI key

MUZQPDBAOYKNLO-RKXJKUSZSA-N

Gene Information

human ... OPRM1(4988)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Oxycodone hydrochloride is an analgesic drug, which is generally used in cancer treatment since it can reduce the pain induced during the treatment.

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Biochem/physiol Actions

μ and κ opioid receptor agonist.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H336

Hazard Classifications

Acute Tox. 4 Oral - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

O1378-BULK:
O1378-VAR:
O1378-500MG:
O1378-1G:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLCG4400
SLBX4974
SLBT8952
SLBS5058
SLBN9282V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Clinical observations on safety and efficacy of OxyContin? administered by rectal route in treating cancer related pain
Li G-C, et al.
Asian Pacific Journal of Cancer Prevention, 12, 2477-2478 (2011)
M Soledad Cepeda et al.
The journal of pain : official journal of the American Pain Society, 14(2), 158-164 (2012-12-21)
Obtaining opioids from multiple prescribers, known as doctor shopping, is 1 example of opioid abuse and diversion. The dual mechanism of action of tapentadol could make tapentadol less likely to be abused than other opioids. The aim of this retrospective
Self-assembly of thermally responsive nanoparticles of a genetically encoded peptide polymer by drug conjugation.
Jonathan R McDaniel et al.
Angewandte Chemie (International ed. in English), 52(6), 1683-1687 (2013-01-03)
Jooyoung Lee
Social science & medicine (1982), 99, 162-168 (2013-09-26)
How do gunshot victims manage pain without health care? This paper examines this question through ethnographic data of a single gunshot victim who self-medicated with Percocet. The observations for this paper were collected in Philadelphia between January of 2010 and
M Comelon et al.
Acta anaesthesiologica Scandinavica, 57(4), 509-517 (2013-01-11)
Targiniq®, an oxycodone prolonged-release (PR) formulation combined with the opioid antagonist naloxone PR, aims to prevent opioid-induced constipation without impairing the analgesic efficacy. This has been confirmed during prolonged use in chronic pain or cancer patients. The purpose of our
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service